Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
$1.78
-2.7%
$1.45
$1.00
$3.00
$12.65M4.58557,460 shs98,864 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.55
+4.4%
$4.51
$2.66
$4.73
$9.37M1.8216,199 shs35,522 shs
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$0.88
+2.9%
$0.99
$0.55
$3.06
$7.64M1.21.92 million shs73,845 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.15
+15.4%
$0.14
$0.06
$6.73
$3.19M0.48581,101 shs154,304 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
-2.73%-7.77%+26.24%+6.59%-5.32%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
0.00%0.00%0.00%+1.79%+19.74%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
+2.85%-4.35%-9.85%-45.00%-18.52%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
+15.40%+16.28%-3.26%+20.64%-97.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
0.5942 of 5 stars
0.02.00.00.02.50.01.3
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
1.5031 of 5 stars
3.03.00.00.00.00.00.6
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1.5804 of 5 stars
3.03.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
0.00
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
0.00
N/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
2.00
Hold$3.00240.91% Upside
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$5.003,202.51% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
$3.11M3.95N/AN/A$2.37 per share0.75
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$3.03M3.09N/AN/A$13.18 per share0.35
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$1.62M4.85N/AN/A($0.03) per share-29.33
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.41N/AN/A($6.91) per share-0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
-$10.16MN/A0.005.09N/A-319.85%-176.55%-93.89%N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$4.59N/AN/A-203.71%-42.56%-39.26%8/4/2025 (Estimated)
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%7/28/2025 (Estimated)

Latest TTOO, NURO, INBS, and POAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
N/A
1.12
0.97
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
13.88
12.70
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/A
0.76
0.75
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24

Institutional Ownership

CompanyInstitutional Ownership
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
32.97%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
9.04%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
0.28%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
3.44%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
106.91 million6.89 millionNot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
202.06 million1.90 millionNot Optionable
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
308.93 million8.63 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable

Recent News About These Companies

T2 Biosystems initiates major layoffs, seeks asset sale
T2 Biosystems to be delisted from Nasdaq
T2 Biosystems reports preliminary Q4 revenue $2.3M
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
T2 Biosystems extends multi-year supplier agreement with Vizient

New MarketBeat Followers Over Time

Media Sentiment Over Time

Intelligent Bio Solutions stock logo

Intelligent Bio Solutions NASDAQ:INBS

$1.78 -0.05 (-2.73%)
Closing price 06/24/2025 03:57 PM Eastern
Extended Trading
$1.80 +0.01 (+0.84%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

NeuroMetrix stock logo

NeuroMetrix NASDAQ:NURO

$4.55 +0.19 (+4.36%)
Closing price 05/1/2025
Extended Trading
$4.55 0.00 (0.00%)
As of 05/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Predictive Oncology stock logo

Predictive Oncology NASDAQ:POAI

$0.88 +0.02 (+2.85%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$0.88 +0.01 (+0.57%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.15 +0.02 (+15.40%)
As of 06/24/2025 03:58 PM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.